Pfizer CEO Albert Bourla says an oral medicine to treat the deadly infection could be available by next year
As the coronavirus wreaks havoc on countries around the world, Pfizer CEO Albert Bourla says an oral medicine to treat the deadly infection could be available by next year. The company is researching two antivirals, one that is injected intravenously and the other that is taken orally, according to Bourla.
Despite the fact that the company is working on two drugs, Albert Bourla stated that oral medication is the company’s priority because it can be administered at home, unlike the injection, which requires a trip to the hospital.
In a statement about the oral drug, the CEO said that it may prove to be more successful than current antivirals against multiple virus variants and that the antiviral’s action is not expected to be subject to mutations.
“Because this one doesn’t work on the spike, we think it would be much more successful against multiple variants. But that’s all the good news. “We’re moving on with the studies now, and we’ll have more news around summer,” the CEO told CNBC.
He added that the company expects to provide a further update over the summer when asked what the appropriate time period will be before the drug hits the market.
According to the CEO, Pfizer will manufacture at least 2.5 billion doses of their vaccine this year, equating to 3 billion doses a year. On Monday, India received 3,359,963 more Covid-19 vaccine doses, bringing the total number of vaccine shots to 145,271,186. Meanwhile, the total number of recovered Covid-19 cases in India has risen to 14,556,209, with 251,827 new cured cases registered on Tuesday.